Previous 10 | Next 10 |
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Marijuana players dominated top performers in healthcare this week ahead of a Republican-led attempt for federal legalization of cannabis in the U.S. Meanwhile, less than favorable quarterly earnings hurt decliners. However, the healthcare stocks ended the week in positive territory with a...
MSCI will be including total 112 companies including Zomedica (NYSE:ZOM), Clovis Oncology (NASDAQ:CLOV), 22nd Century (NASDAQ:XXII), Omeros (NASDAQ:OMER) and Verastem (NASDAQ:VSTM) in its MSCI US Micro Cap Index as a part of Semi-Annual Index Review. MSCI excluded a...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This is certainly one of the most intriguing markets we’ve seen in some time. Growth stocks are flying, as are valuations. Investors appear to be taking the “TINA” (there is no alternative) trade to the...
Neurological diseases including Alzheimer's are a huge unmet need that BIIB and SAVA are working on solutions for. BIIB's diversification, low sentiment, and profitability make it more suitable to a wider audience of investors. SAVA's simufilam Phase 3 trials are getting underway ...
The company's Q3 earnings "missed" expectations which is laughable. Cassava is increasing spending to get its phase 3 trials off the ground. Two cash raises in the last year should be enough to carry the company through Phase 3 readouts, but the possibility of a surprise cash rais...
Biogen's struggles with Aduhelm - its newly approved Azheimer's therapy - have been well documented - but the company is taking some small steps in the right direction. Meanwhile, Cassava Sciences recently took a significant step to restoring its own reputation - and share price - aft...
Cassava Sciences (SAVA -4.6%) is trading lower in morning hours after the company released its Q3 financials for 2021. While the earnings release did not include any updates on its much-sought-after clinical program on potential Alzheimer’s therapy, simufilam, the company has rais...
Cassava Sciences (NASDAQ:SAVA): Q3 GAAP EPS of -$0.24 misses by $0.09. At September 30, 2021, cash and cash equivalents were $241.5 million, compared to $93.5 million at December 31, 2020, with no debt. Shares -4.74% PM. Press Release For further details see: Cassava Sciences EPS misses...
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2021. Net loss for the third quarter ended Septem...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...